Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
- Published In:
- Menopause (New York, N.Y.), 27(10), 1137-1142 (2020)
- Authors:
- Greenspan, Susan L, Fitzpatrick, Lorraine A, Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C, Deal, Chad, Cosman, Felicia, McClung, Michael
- Database ID:
- RPEP-04826
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04826APA
Greenspan, Susan L; Fitzpatrick, Lorraine A; Mitlak, Bruce; Wang, Yamei; Harvey, Nicholas C; Deal, Chad; Cosman, Felicia; McClung, Michael. (2020). Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.. Menopause (New York, N.Y.), 27(10), 1137-1142. https://doi.org/10.1097/GME.0000000000001593
MLA
Greenspan, Susan L, et al. "Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.." Menopause (New York, 2020. https://doi.org/10.1097/GME.0000000000001593
RethinkPeptides
RethinkPeptides Research Database. "Abaloparatide followed by alendronate in women ≥80 years wit..." RPEP-04826. Retrieved from https://rethinkpeptides.com/research/greenspan-2020-abaloparatide-followed-by-alendronate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.